Acuta Capital Partners, LLC Gh Research PLC Transaction History

Acuta Capital Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.88 - $12.74 $12,434 - $20,103	1,578 Added 0.65%	244,828 $2.91 Million
Q2 2022 Aug 15, 2022	SELL	$8.99 - $19.87 $1.59 Million - $3.5 Million	-176,382 Reduced 42.03%	243,250 $2.43 Million
Q4 2021 Feb 14, 2022	BUY	$14.1 - $27.9 $371,986 - $736,057	26,382 Added 6.71%	419,632 $9.79 Million
Q3 2021 Nov 15, 2021	BUY	$16.51 - $23.68 $4.02 Million - $5.76 Million	243,250 Added 162.17%	393,250 $8.68 Million
Q2 2021 Aug 16, 2021	BUY	$19.25 - $21.73 $2.89 Million - $3.26 Million	150,000 New	150,000 $3.26 Million

23.5M

63.1K

1.9K

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $340M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.